62 results about "Hiv disease" patented technology

This invention provides a method for synthesizing the anti-AIDS drug enovirine. This invention belongs to the field of pharmaceutical preparation technology. The synthesis method includes the following steps: (1) SM1 compound reacts with Grignard reagent and then reacts with SM2 compound to obtain compound III; (2) Compound III undergoes oxidation reaction to obtain compound II; (3) Compound II undergoes demethylation reaction under the action of demethylation reagent to obtain compound I; (4) Compound I undergoes ethylation reaction to obtain enovirine. The synthesis route of this invention effectively avoids the use of highly toxic cyanide reagents and expensive heavy metal catalysts. At the same time, the reaction conditions of this route are simple and mild, with high yield, and have excellent industrialization prospects.

The invention belongs to the technical field of medicines, and particularly relates to pyrrolo [2, 3-d] pyrimidine compounds of aryl fragments and piperidine fragments as well as a preparation method and application of the pyrrolo [2, 3-d] pyrimidine compounds. The pyrrolo [2, 3-d] pyrimidine compound containing the aryl fragment and the piperidine fragment is an HIV-1 reverse transcriptase inhibitor, and the pyrrolo [2, 3-d] pyrimidine compound further comprises pharmaceutical salt, hydrate and solvate of the pyrrolo [2, 3-d] pyrimidine compound, polycrystal or eutectic of the pyrrolo [2, 3-d] pyrimidine compound, and precursors and derivatives with the same biological functions of the pyrrolo [2, 3-d] pyrimidine compound. The invention also relates to a preparation method of the compound and application of a composition containing one or more of the compounds in related medicines for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

The application discloses a kind of diaromatic pyrimidine compounds containing fused heterocycle and preparation method and application thereof.The compound has the structure shown in general formula I.The application further relates to pharmaceutical compositions containing the compound of formula I.Active screening experiments show that the compound of the application has good anti-HIV and CHIKV activity, and therefore the application further provides the use of the above-mentioned compound in the preparation of anti-AIDS drugs and anti-Chikungunya virus drugs.

The invention discloses application of a gp130 inhibitor in preparation of a medicine for treating virus infection, and relates to the technical field of medicines. Experiments prove that combination of IL-6 family cell factors and a gp130 receptor is inhibited, so that downward signal transmission of a JAK2 / STAT3 signal channel triggered by the IL-6 family cell factors is inhibited, the purposes of inhibiting cell fusion induced by SARS-CoV-2 spike protein and further influencing replication and propagation of SARS-CoV-2 are achieved, and a small-molecule inhibitor SC144 is an inhibitor of gp130, has a remarkable effect of inhibiting SARS-CoV-2 virus replication and has a good application prospect. Meanwhile, the traditional Chinese medicine composition also has a remarkable effect of inhibiting replication of viruses such as human immunodeficiency virus, herpes simplex virus and respiratory syncytial virus.

A compound of formula I or a stereoisomer, isotopic isomer, tautomer or pharmaceutically acceptable salt thereof: wherein a ligand that binds to Nef protein (NB) is covalently linked to a ligand that binds to E3 ligase cerebron (CB) via a linker (L).

The invention discloses an AIDS (acquired immune deficiency syndrome) short-term amplification prediction and early warning method and device, electronic equipment and a medium, which are used for solving the problem of how to effectively predict the short-term growth trend of AIDS cases in a region and give an early warning in time under the conditions of short data time span and sparse data. Acquiring newly added data and public attention data of the AIDS cases in the preset time window up to the month in the to-be-detected area; wherein the to-be-detected area comprises a plurality of sub-areas; inputting the newly added data of the AIDS cases and the public attention data into a short-term amplification prediction model for binary pre-training based on a unified large model framework and joint parameter fine tuning, and outputting prediction probabilities of reaching the preset AIDS case amplification in the next month of each sub-region through binary prediction; and for each sub-region, when the prediction probability indicates that the number of newly added AIDS cases in the next month of the sub-region meets a preset AIDS case amplification early warning condition, generating an early warning suggestion of the sub-region.

The invention relates to the technical field of biological medicines, in particular to an injection for treating AIDS and a preparation method thereof. The extraction method of the sulfate algae polysaccharide comprises the following steps: mixing seaweed meal, cellulase and water, carrying out enzymolysis, and extracting for 10-12 hours to obtain an extract; filtering, adding magnesium chloride hexahydrate into filtrate, standing for 20-30 minutes, centrifuging, taking supernatant, removing impurities, adding absolute ethyl alcohol until the final concentration is 55-65%, and precipitating polysaccharide; and purifying the precipitated crude polysaccharide, and freeze-drying to obtain the sulfate algae polysaccharide. The purity of the sulfate algae polysaccharide is greater than or equal to 95%, and the sulfate algae polysaccharide is cooperated with lentinan to obtain a safe and stable injection with an excellent treatment effect on AIDS (Acquired Immune Deficiency Syndrome). And a new scheme is provided for treatment of AIDS.

The invention relates to the technical field of traditional Chinese medicine extract fermentation, and provides a microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method for treating AIDS and application of microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method.The microspore ganoderma lucidum immune protein and herba houttuyniae fermentation method comprises the steps that microspore ganoderma lucidum strains and herba houttuyniae fermentation liquor are co-fermented, beta-cyclodextrin-selenocystine of a specially-made additive is combined, and the microspore ganoderma lucidum immune protein is obtained; the problems that in traditional AIDS treatment, latent infection cells are difficult to remove, toxic and side effects of drugs are remarkable, and the reconstruction efficiency of an immune system is low are effectively solved, experiments prove that the fermentation product can activate the immune system, the cell number and the dendritic cell maturity are remarkably improved, and the curative effect is good. Meanwhile, the multi-target antiviral effect is achieved by blocking virus envelope combination, inhibiting reverse transcriptase activity and inducing latent infection cell apoptosis; the anti-oxidation and anti-inflammatory characteristics can reduce the risk of opportunistic infection, reduce the toxic damage of antiviral drugs to liver, kidney and intestinal tracts, and provide a new scheme for comprehensive treatment of AIDS and nutrition support of patients.

The present invention relates to the technical field of drug for treatment of AIDS. Disclosed are a polycyclic carbamoyl pyridone derivative, a preparation method therefor, and pharmaceutical composition thereof. The derivative comprises the compound represented by formula (I)-1 or formula (I)-2, or an isomer, pharmaceutically acceptable salt, hydrate or solvate thereof. At least one group of functional groups in (1)-(3) below and a ring A form a spirolcycle or spiroheterocycle: (1) R1 and R2; (2) R3 and R4; (3) R5 and R6; the polycyclic carbamoyl pyridone derivative can selectively inhibit the activity of HIV integrase, and thus can be used for preventing and treating AIDS.

The invention discloses an application of a PHD3 inhibitor in prevention and treatment of AIDS (acquired immune deficiency syndrome). Through multidisciplinary research means of immunology, biochemistry and the like, the situation that virus antisense protein ASP inhibits generation of I-type IFN in the HIV-1 infection process is analyzed, immune escape is achieved, and a latent infection mechanism is established. In the aspect of mechanism, the ASP can play the inhibiting role after transcriptional expression into protein in a body cell through post-translational modification, the 47-site proline of the ASP can be helped to realize the capability of inhibiting the immune response of the body after hydroxylation modification, and the post-translational modification is realized by depending on proline hydroxylase 3 (PHD3) of a host. On the basis of mechanism research, it is found that a PHD3 inhibitor Molidustat counteracts hydroxylation of PHD3 to ASP, so that immune escape of HIV-1 is blocked, infection is antagonized, and good development prospects of AIDS treatment and prevention drugs are shown.

The application discloses a kind of chronic infectious disease digital people health management system construction method, it relates to AIDS nursing management technical field.Based on Triangle model, the management classification and characteristics of HIV patients are determined by latent profile and association rule analysis, and it is embedded into applet using agile development;Based on the basic nursing framework, the commonality and difference of patients in different levels are explored Care needs;Through the preliminary construction of AIDS hierarchical case management program by range review and focus group interview, the final draft is formed by revising and improving through written evaluation and field demonstration, and the well-constructed management program is embedded into a digital human interaction platform based on artificial intelligence.The application protects the privacy of patients, alleviates the shortage of medical human resources, meets the growing health needs of HIV patients, improves patient satisfaction and improves the quality of HIV care services.

The application provides a 4-quinazolinone derivative containing a benzene sulfonamide piperazine ketone and a preparation method and application thereof. The derivative has the structure shown in the following general formula I. The application further relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / HIV-2 capsid protein regulator in preparation of an anti-AIDS drug.

The invention belongs to the technical field of medicines, and particularly relates to a dihydropteridine-6 (5H)-ketone skeleton compound as well as a preparation method and application thereof. The dihydropteridine-6 (5H)-ketone skeleton compound disclosed by the invention is an HIV-1 (Human Immunodeficiency Virus-1) non-nucleoside reverse transcriptase inhibitor; the invention also comprises pharmaceutical salts, hydrates, solvates, polycrystals or co-crystals of the compounds, precursors and derivatives with the same biological functions of the compounds, a preparation method of the compounds and application of a composition containing one or more of the compounds in preparation of related drugs for treating AIDS and the like. The result of an in-vitro cellular level anti-HIV-1 activity experiment shows that the micromolecule has relatively strong anti-HIV-1 biological activity, can remarkably inhibit virus replication in MT-4 cells infected by HIV-1 viruses, and has relatively low cytotoxicity.

Provided are membrane fusion inhibitors, derivatives thereof, pharmaceutical compositions thereof, and pharmaceutical uses thereof for inhibiting HIV and drug-resistant strains thereof.

The invention discloses an application of a UFMylation regulator in preparation of a medicine for resisting HIV (Human Immunodeficiency Virus) infection. According to the application disclosed by the invention, through in-vivo and in-vitro pharmacodynamic experiments, the inhibition effect of a UFMylation regulator, namely a UFSP2 inhibitor Compond-8, on an HIV (Human Immunodeficiency Virus) is evaluated. Experimental results show that the Compound 8 can significantly inhibit the replication of MT-4 cells, primary CD4 + T cells and HIV viruses in mice, can still maintain low virus load after drug withdrawal, has no obvious influence on the proliferation of normal cells and the weight of mice, and has a good anti-HIV infection effect and high safety. The invention reveals that the Compound 8 effectively inhibits HIV-1 replication for the first time, prompts that the Compound 8 can be used as a candidate drug of an HIV-1 treatment drug, provides a new treatment strategy for AIDS, and has a wide application prospect in the field of HIV infection resistance.

Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and / or L-GP130. HIL-6 or L-GP130 continuous overexpression / conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS.

To provide a therapeutic or prophylactic vaccine for HIV disease.SOLUTION: A composition for delivering an antigen-expression system is provided, wherein the antigen-expression system comprises a vector backbone comprising a chimpanzee adenovirus vector, which is optionally a ChAdV68 vector, or an alphavirus vector, which is optionally a Venezuelan equine encephalitis virus vector, wherein the vector backbone comprises at least one HIV MHC class I antigen-encoding nucleotide sequence comprising an MHC class I epitope-encoding nucleotide sequence, wherein optionally the MHC class I epitope-encoding nucleotide sequence encodes an MHC class I epitope comprising at least one HIV epitope selected from the group consisting of the specified sequences.SELECTED DRAWING: Figure 34

The application provides a complex tablet of darunavir and cobicistat and a preparation method thereof, and the preparation method is as follows: darunavir ethanolate, part of a first disintegrant and a first lubricant are put into a dry granulator, granulation and whole granulation are carried out to obtain dry granules; hydroxypropyl methyl cellulose and proper water are mixed to form a binder solution, the dry granules and the rest of the first disintegrant are mixed, the binder solution is sprayed, and wet granulation is carried out, drying and whole granulation are carried out to obtain wet granules; the wet granules, silica loaded with cobicistat, a second disintegrant and a filler are mixed until uniform, then sieved, and a second lubricant is added and mixed again; tabletting is carried out, and then film coating is carried out. The application combines darunavir and cobicistat to prepare a medicine, reduces drug resistance caused by single drug use, and provides more choices for AIDS patients. In addition, the complex tablet can improve the content of darunavir.

A prophylactic or therapeutic pharmaceutical agent for HIV infectious diseases, said pharmaceutical agent being characterized by comprising a combination of: (A) a compound represented by formula (I) (wherein ring A represents a non-aromatic heterocyclic ring; ring B represents a benzene ring or a pyridine ring; Q represents —NHC(O)—or the like; each R1 independently represents a halogen atom or the like; each of R1a and R1b independently represents a hydrogen atom or the like, R2represents an alkyl group or a haloalkyl group, R3represents a hydrogen atom or an alkyl group; and n represents an integer from 1 to 3) or a pharmaceutically acceptable salt thereof; and (B) a compound having an anti-HIV effect or a pharmaceutically acceptable salt thereof.

The invention provides a compound containing an indoleacetamide-fluorophenylalanine-hydroxyproline structure as well as a preparation method and application of the compound. The derivative has a structure as shown in a general formula I. The invention also relates to a preparation method of the compound and application of the compound as an HIV-1 capsid protein degradation agent in preparation of anti-AIDS drugs. # imgabs0 #

The application of the deubiquitinase to the immune reconstitution incomplete prediction target of the AIDS patient comprises the following steps: identifying that the ubiquitinase is YOD1 and has obvious interaction with HIV virus protein Nef; identifying that the YOD1 stabilizes the HIV auxiliary protein Nef through the protein level instead of the RNA level; identifying that the YOD1 can prolong the half-life period of the HIV auxiliary protein Nef; the YOD1 is identified to enhance the expression level of Nef in virus particles of an HIV NL4-3 clone strain by reducing the ubiquitination of the Nef protein of HIV-1 (Human Immunodeficiency Virus 1) and influence the ubiquitination of the K6 site of the Nef protein; identifying that YOD1 inhibits ubiquitination of Nef protein and stabilizes the Nef protein; yOD1 is identified to be in positive correlation with Nef under the HIV infection condition, and the positive correlation is increased along with the increase of the infection dose or the infection time; it is identified that YOD1 promotes virus replication by stabilizing the Nef protein level and aggravates loss of CD4 + T cells, and the expression level of YOD1 is in positive correlation with immune imperfection of an HIV-1 infected person; it is identified that the vitamin C can effectively lower the expression level of YOD1 and Nef protein, and then the virus virulence is reduced.

Provided in the present invention are novel compounds, a composition thereof, a preparation method therefor and the use thereof. The compounds (I) and the composition thereof of the present invention have a significant anti-human immunodeficiency virus effect, and have significantly improved in-vivo bioavailability.

The present application relates to a kind of multispecific and / or multivalent binding protein for preventing and / or treating HIV infection, it includes at least 3 antigen binding sites, part of antigen binding site is specifically bound HIV-1-gp41 or HIV-1-gp120 or HIV-1-gp160, still part of antigen binding site is specifically bound human CD4 receptor or human CCR5 receptor;The binding protein of the present application has excellent broad-spectrum neutralizing ability in the treatment or prevention of HIV infection, provides a new solution for the problem of drug resistance escape caused by HIV virus variation, in addition, the present application inventor also unexpectedly found that the binding protein of the present application can treat or prevent the tumor-related disease caused by HIV infection.

The application provides a benzene sulfonamide piperazine ketone glycine derivative and a preparation method and application thereof. The derivative has a structure shown in the following general formula I. The application also relates to a preparation method of a compound containing the structure of formula I and application of the compound as an HIV-1 / 2 capsid protein regulator in preparation of an anti-AIDS drug.

Disclosed herein are identified compound fragments, compounds and their pharmaceutically acceptable salts, isotopes or solvates, useful as antiviral drug and / or as a hepatic-targeted drug, such as for the treatment of HBV, HDV and / or HIV.

This invention provides primer sets, probes, kits for expressing interferon-stimulated genes IFI27 and IFI6, and their use in evaluating the immune reconstitution status of HIV-infected individuals.

The application provides a kit for anti-AIDS drug detection and a detection method of anti-AIDS drugs, the kit comprises a sample stable control liquid, a mixed internal standard working liquid, a protein precipitant, a special reconstitution solution, a standard and a quality control; the sample stable control liquid comprises a buffer solution containing sodium fluoride and EDTA-2Na. The kit and the detection method provided by the application realize in-vitro stable control of a very low degradation level of prodrug components, guarantee the authenticity of source data of clinical diagnosis, overcome the technical prejudice that weak ionization components cannot be detected by positive ions, significantly improve the detection flux and the quantitative precision of a narrow treatment window, perfectly balance the physical solvent behavior of 'large polarity span' components, completely eliminate the matrix inhibition at dead volume, and establish the highest standard quantitative mechanism of full isotope matching, have very high anti-interference ability and compliance, and can simultaneously quantitatively detect seven anti-AIDS drugs in biological samples.

The application discloses a proteolysis body (PROTAC) targeting HIV protease and application thereof, the PROTAC is a polypeptide structure, a general formula is R1-L-E3L or R1-L-E3L-R2, wherein R1 is a target ligand of HIV protease, L is a GSGS linker, E3L is a ligand of VHL (von Hippel-Lindau) E3 ubiquitin ligase, and R2 is a D-configuration arginine cell penetration peptide; the PROTAC can recruit E3 ligase, specifically induce ubiquitination and degradation of HIV protease in a proteasome-dependent manner; the application further provides a gene encoding the PROTAC, a recombinant carrier, a pharmaceutical preparation and application of the gene in preparation of an anti-AIDS drug.

The purpose of the present invention is to provide a method for detecting whether a subject is infected with AIDS virus (HIV) or is in a latent HIV infection state, or whether the subject is suspected of being infected with HIV or being in a latent HIV infection state.　The present invention provides a method for determining whether a mammalian subject is infected with HIV or is in a latent HIV infection state, or whether the mammalian subject is suspected of being infected with HIV or being in a latent HIV infection state, the method involving: a step for detecting the amount of 3-methylcytidine (m3C) in a sample derived from the subject; and a step for providing information on the detected amount for the determination.

The invention discloses application of acridine compounds in preparation of anti-human immunodeficiency virus drugs, and belongs to the field of preparation of antiviral drugs. Experiments find that the compound can significantly improve the latent HIV-1 transcriptional activity in the body of a patient when being used for preparing drugs for treating AIDS, so that the compound can be recognized by anti-retrovirus drugs. Taking HIV-1 latent infection cells as an example, the compound enables the expression quantity of HIV-1 virus genes to be remarkably improved, and has the potential of activating a virus repository. Therefore, the compound has the potential of eliminating the virus latent library in the body of an AIDS patient, and provides a new possibility for functional cure of AIDS.